At the outset of the COVID pandemic, doctors and scientists were looking for successful treatments that could reduce the toll of the virus. At this stage, quite a few promising candidates have appeared, many of whom are already in the market to treat other diseases. Now another potential COVID treatment joins the list in the form of a widely available and extensively tested inhaler, traditionally used to treat asthma and chronic obstructive pulmonary disease (COPD). According to a new study by the NIHR Oxford Biomedical Research Center (BRC), which has not yet been peer-reviewed, the drug budesonide has been found to reduce the risk of serious diseases by 90 percent. Read on to find out more about this groundbreaking treatment for COVID, and for the latest vaccination news, visit Dr. Fauci. You will easily make an appointment with a vaccine after this date.
Taking into account a total of 146 subjects, the researchers gave half of the group a budesonide inhaler for twice daily doses of 800 micrograms, and the other half a placebo for a period of 28 days. Those who took the treatment were not only 90 percent less likely to take urgent care, but also reportedly benefited from shorter fever and fewer long-term symptoms.
“I am encouraged to see the decrease in persistent symptoms 14 and 28 days after treatment with budesonide,” Mona Bafadhel, MD, a professor and respiratory consultant who also works at the Oxford University Hospitals NHS Foundation Trust, shared on the Oxford University website. “Persistent symptoms after the initial COVID-19 disease have emerged as a long-term problem. Any intervention that can address this will be an important step forward,” she added.
The study was apparently inspired by the observation that few chronic asthma patients were admitted to the hospital in the first months of the pandemic. The findings may confirm that this tendency was due to the use of corticosteroid inhalers that prevent severe respiratory effects. If confirmed, the discovery could save countless lives.
“The vaccination programs are very exciting, but we know it will take a while to reach everyone around the world,” Bafadhel said. ‘I am delighted that a relatively safe, widely available and well-studied drug such as an inhaled steroid’ has an impact on the pressure we are experiencing during the pandemic. ‘
Are you wondering how else you can reduce your serious COVID risk? Read on for more ways to keep the virus in check, and for more information on your potential risk level, see If you have this common habit, your COVID symptoms will be worse.
Budesonide is not the only drug already on the market that can fight COVID. According to a recent Canadian study, which has not yet been evaluated by peers, an anti-inflammatory medication for gout called colchicine can also significantly reduce the rate of hospitalization and deaths due to the new coronavirus.
The researchers insist that colchicine in addition to these benefits is also inexpensive, administered orally and that it has few known side effects. In addition, the team reported that the treatment group had fewer cases of pneumonia, and showed a reduced need for supplemental oxygen. And for more medications that could potentially help prevent serious cases, you can consult these medications to reduce the risk of COVID death, experts say.
New research also shows that those who take a daily dose of aspirin may experience better COVID outcomes than those who do not.
One study in October in the journal Anesthesia and analgesia reviewed the medical records of more than 400 coronavirus patients admitted to the hospital from March to July. Among the patients, it was found that those who took a low dose of aspirin daily were 43 percent less likely to be transferred to the intensive care unit (ICU) and that 44 percent were less likely to be placed in a ventilator. Finally, the same patients were 47 percent less likely to die from COVID than patients who did not take aspirin daily. And to prevent you from contracting the virus in the first place, you need to find out where you are likely to catch COVID, says new study.
According to a December study that has yet to be judged by a peer, a simple nasal spray can have a profound effect on the new coronavirus. Through in vitro experiments, researchers found that Xlear Sinus Care can help neutralize COVID-19: it could significantly reduce the amount of active COVID virus after only 25 minutes.
Ingredients of the spray include xylitol – a chemical compound often used as a sweetener – as well as .2 percent grapefruit seed extract (GSE) and .85 percent salt. “Combination therapy with GSE and xylitol can prevent the spread of viral respiratory infections, not only for SARS-CoV-2 but also for future H1N1 or other viral epidemics,” the study authors wrote. “GSE significantly reduces the virus charge while xylitol prevents the virus from attaching to the nuclear protein on the cell wall.” And sign up for our daily newsletter for more COVID news sent straight to your inbox.
Blood clots are a common occurrence with COVID, affecting about one-third of serious patients, according to a meta-analysis in January published in the journal. Medical hypotheses. And so blood thinners may be the answer. In a study of February 2021 published in The BMJ, researchers examined data on 4,297 COVID patients from the U.S. Department of Veterans Affairs whose average age was 68. They found that COVID patients who received blood thinners within 24 hours of being admitted to the hospital saw their risk of death reduced by 34 percent. compared to individuals who did not receive the medication.
Although more research is needed, the study’s authors say their findings “provide strong evidence from the real world to support guidelines that recommend the use of preventative anticoagulation as initial treatment for patients with COVID-19 during hospitalization.” And for more information on what can reduce your COVID risk, visit these 3 vitamins that can save you from serious COVID study funds.